Neurogene Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Neurogene Inc. (NGNE) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2021-03-25
- Neurogene Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2019-12-31 was $0.00.
- Neurogene Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2019-09-30 was $47.72M.
- Neurogene Inc. research and development asset acquired other than through business combination, written-off for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Neurogene Inc. research and development asset acquired other than through business combination, written-off for fiscal 2019 was $47.72M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $47.72M derived: sum of 2 quarters · filed 2021-03-25 | $47.72M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $47.72M 10-Q · filed 2020-11-09 | $47.72M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |